Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Rhythm Pharmaceuticals (RYTM) Assets Average (2017 - 2025)

Rhythm Pharmaceuticals (RYTM) has disclosed Assets Average for 9 consecutive years, with $493.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Assets Average rose 30.59% to $493.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $493.5 million, a 30.59% increase, with the full-year FY2025 number at $436.2 million, up 20.34% from a year prior.
  • Assets Average was $493.5 million for Q4 2025 at Rhythm Pharmaceuticals, up from $439.8 million in the prior quarter.
  • In the past five years, Assets Average ranged from a high of $493.5 million in Q4 2025 to a low of $281.2 million in Q2 2022.
  • A 5-year average of $359.2 million and a median of $353.8 million in 2023 define the central range for Assets Average.
  • Peak YoY movement for Assets Average: surged 62.15% in 2021, then crashed 30.61% in 2022.
  • Rhythm Pharmaceuticals' Assets Average stood at $342.7 million in 2021, then rose by 12.66% to $386.0 million in 2022, then decreased by 11.03% to $343.5 million in 2023, then grew by 10.03% to $377.9 million in 2024, then soared by 30.59% to $493.5 million in 2025.
  • Per Business Quant, the three most recent readings for RYTM's Assets Average are $493.5 million (Q4 2025), $439.8 million (Q3 2025), and $379.7 million (Q2 2025).